113 related articles for article (PubMed ID: 22428685)
21. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
22. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.
Xia H; Gu G; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Song Q; Yao L; Tu Y; Chen H; Gao X; Chen J
Bioconjug Chem; 2013 Mar; 24(3):419-30. PubMed ID: 23350619
[TBL] [Abstract][Full Text] [Related]
23. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers.
Li G; Low PS
Bioorg Med Chem Lett; 2015 Apr; 25(8):1792-1798. PubMed ID: 25791453
[TBL] [Abstract][Full Text] [Related]
25. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
26. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
[TBL] [Abstract][Full Text] [Related]
28. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
29. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
30. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
31. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Iwase Y; Maitani Y
Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
[TBL] [Abstract][Full Text] [Related]
32. [VCR-loaded nanoparticles as targeted delivery system for the treatment of orbital adenoid cystic carcinoma].
He YJ; Lin TT; Zhu LM; Luo H; Chang J; Zhang H; Zhang HM
Zhonghua Yan Ke Za Zhi; 2010 Sep; 46(9):795-801. PubMed ID: 21092558
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of L-type calcium channels by octreotide in isolated human neuroendocrine tumor cells of the gut.
Glassmeier G; Höpfner M; Riecken EO; Mann B; Buhr H; Neuhaus P; Meyerhof W; Scherübl H
Biochem Biophys Res Commun; 1998 Sep; 250(2):511-5. PubMed ID: 9753663
[TBL] [Abstract][Full Text] [Related]
34. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
Devalapally H; Shenoy D; Little S; Langer R; Amiji M
Cancer Chemother Pharmacol; 2007 Mar; 59(4):477-84. PubMed ID: 16862429
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
36. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
38. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
39. Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging.
Orocio-Rodríguez E; Ferro-Flores G; Santos-Cuevas CL; Ramírez Fde M; Ocampo-García BE; Azorín-Vega E; Sánchez-García FM
J Nanosci Nanotechnol; 2015 Jun; 15(6):4159-69. PubMed ID: 26369025
[TBL] [Abstract][Full Text] [Related]
40. In vivo molecular imaging of somatostatin receptors in pancreatic islet cells and neuroendocrine tumors by miniaturized confocal laser-scanning fluorescence microscopy.
Fottner C; Mettler E; Goetz M; Schirrmacher E; Anlauf M; Strand D; Schirrmacher R; Klöppel G; Delaney P; Schreckenberger M; Galle PR; Neurath MF; Kiesslich R; Weber MM
Endocrinology; 2010 May; 151(5):2179-88. PubMed ID: 20233796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
